bioRxiv preprint doi: https://doi.org/10.1101/533174; this version posted January 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Pharmacological inhibition of GPR4 remediates intestinal inflammation in a mouse colitis model Edward J. Sanderlina, Mona Mariea, Juraj Velcickyc, Pius Loetscherc, Li V. Yanga,b,* aDepartment of Internal Medicine, Brody School of Medicine, East Carolina University, USA bDepartment of Anatomy and Cell Biology, Brody School of Medicine, East Carolina University, USA cNovartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland * Corresponding author: Li V. Yang, Ph.D., Department of Internal Medicine, Brody School of Medicine, East Carolina University, 600 Moye Blvd., Greenville, NC 27834, U.S.A. Email:
[email protected]; Phone: +1-252-744-3419 bioRxiv preprint doi: https://doi.org/10.1101/533174; this version posted January 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Inflammatory bowel disease (IBD) is characterized by chronic, recurring inflammation of the digestive tract. Current therapeutic approaches are limited and include biologics and steroids such as anti-TNFα monoclonal antibodies and corticosteroids, respectively. Significant adverse drug effects can occur for chronic usage and include increased risk of infection in some patients.